Clinical characteristics of leukemia patients and healthy subjects included in the human pilot study
| . | Age . | Sex . | Drug . | Dose . | Relevant comedication . |
|---|---|---|---|---|---|
| Control | |||||
| 1 | 62 | F | — | — | — |
| 2 | 31 | F | — | — | — |
| 3 | 52 | M | — | — | — |
| 4 | 28 | M | — | — | — |
| 5 | 48 | F | — | — | — |
| Mean | 44.2 | ||||
| Imatinib | |||||
| 1 | 60 | F | Imatinib | 400 mg | — |
| 2 | 72 | M | Imatinib | 400 mg | — |
| 3 | 49 | M | Imatinib | 400 mg | — |
| Mean | 60.3 | ||||
| Dasatinib/bosutinib | |||||
| 1 | 31 | F | Dasatinib | 140 mg | — |
| 2 | 59 | F | Dasatinib | 140 mg | anagrelide (1 mg OD) |
| 3 | 61 | M | Bosutinib | 500 mg | ASA (100 mg OD) |
| 4 | 66 | F | Dasatinib | 140 mg | — |
| Mean | 54.3 |
| . | Age . | Sex . | Drug . | Dose . | Relevant comedication . |
|---|---|---|---|---|---|
| Control | |||||
| 1 | 62 | F | — | — | — |
| 2 | 31 | F | — | — | — |
| 3 | 52 | M | — | — | — |
| 4 | 28 | M | — | — | — |
| 5 | 48 | F | — | — | — |
| Mean | 44.2 | ||||
| Imatinib | |||||
| 1 | 60 | F | Imatinib | 400 mg | — |
| 2 | 72 | M | Imatinib | 400 mg | — |
| 3 | 49 | M | Imatinib | 400 mg | — |
| Mean | 60.3 | ||||
| Dasatinib/bosutinib | |||||
| 1 | 31 | F | Dasatinib | 140 mg | — |
| 2 | 59 | F | Dasatinib | 140 mg | anagrelide (1 mg OD) |
| 3 | 61 | M | Bosutinib | 500 mg | ASA (100 mg OD) |
| 4 | 66 | F | Dasatinib | 140 mg | — |
| Mean | 54.3 |
OD, once daily.